| Down syndrome SE Antonarakis, BG Skotko, MS Rafii, A Strydom, SE Pape, DW Bianchi, ... Nature Reviews Disease Primers 6 (1), 9, 2020 | 699 | 2020 |
| Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial S Craft, R Raman, TW Chow, MS Rafii, CK Sun, RA Rissman, ... JAMA neurology 77 (9), 1099-1109, 2020 | 278 | 2020 |
| Recent developments in Alzheimer's disease therapeutics MS Rafii, PS Aisen BMC medicine 7, 1-4, 2009 | 271 | 2009 |
| A phase II trial of huperzine A in mild to moderate Alzheimer disease MS Rafii, S Walsh, JT Little, K Behan, B Reynolds, C Ward, S Jin, ... Neurology 76 (16), 1389-1394, 2011 | 256 | 2011 |
| A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease MS Rafii, TL Baumann, RAE Bakay, JM Ostrove, J Siffert, AS Fleisher, ... Alzheimer's & dementia 10 (5), 571-581, 2014 | 234 | 2014 |
| Agrin and microvascular damage in Alzheimer’s disease TM Berzin, BD Zipser, MS Rafii, V Kuo—Leblanc, GD Yancopouloš, ... Neurobiology of aging 21 (2), 349-355, 2000 | 217 | 2000 |
| Adeno-associated viral vector (serotype 2)–nerve growth factor for patients with alzheimer disease: a randomized clinical trial MS Rafii, MH Tuszynski, RG Thomas, D Barba, JB Brewer, RA Rissman, ... JAMA neurology 75 (7), 834-841, 2018 | 185 | 2018 |
| A phase 3 trial of IV immunoglobulin for Alzheimer disease NR Relkin, RG Thomas, RA Rissman, JB Brewer, MS Rafii, CH Van Dyck, ... Neurology 88 (18), 1768-1775, 2017 | 168 | 2017 |
| Alzheimer's disease associated with Down syndrome: a genetic form of dementia J Fortea, SH Zaman, S Hartley, MS Rafii, E Head, M Carmona-Iragui The Lancet Neurology 20 (11), 930-942, 2021 | 156 | 2021 |
| High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment S Kovacevic, MS Rafii, JB Brewer, ... Alzheimer Disease & Associated Disorders 23 (2), 139-145, 2009 | 142 | 2009 |
| Outcome measures for clinical trials in Down syndrome AJ Esbensen, SR Hooper, D Fidler, SL Hartley, J Edgin, XL d'Ardhuy, ... American journal on intellectual and developmental disabilities 122 (3), 247-281, 2017 | 137 | 2017 |
| Agrin in Alzheimer’s disease: altered solubility and abnormal distribution within microvasculature and brain parenchyma JE Donahue, TM Berzin, MS Rafii, DJ Glass, GD Yancopoulos, JR Fallon, ... Proceedings of the National Academy of Sciences 96 (11), 6468-6472, 1999 | 132 | 1999 |
| Advances in Alzheimer’s disease drug development MS Rafii, PS Aisen BMC medicine 13 (1), 62, 2015 | 128 | 2015 |
| Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: a randomized clinical trial CH Van Dyck, HB Nygaard, K Chen, MC Donohue, R Raman, ... JAMA neurology 76 (10), 1219-1229, 2019 | 124 | 2019 |
| Trial of solanezumab in preclinical Alzheimer’s disease RA Sperling, MC Donohue, R Raman, MS Rafii, K Johnson, CL Masters, ... New England Journal of Medicine 389 (12), 1096-1107, 2023 | 106 | 2023 |
| The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual … JA Moran, MS Rafii, SM Keller, BK Singh, MP Janicki Mayo Clinic Proceedings 88 (8), 831-840, 2013 | 105 | 2013 |
| The AHEAD 3‐45 Study: design of a prevention trial for Alzheimer's disease MS Rafii, RA Sperling, MC Donohue, J Zhou, C Roberts, MC Irizarry, ... Alzheimer's & dementia 19 (4), 1227-1233, 2023 | 96 | 2023 |
| PET imaging of tau pathology and relationship to amyloid, longitudinal MRI, and cognitive change in Down syndrome: results from the Down Syndrome Biomarker Initiative (DSBI) MS Rafii, AS Lukic, RD Andrews, J Brewer, RA Rissman, SC Strother, ... Journal of Alzheimer's Disease 60 (2), 439-450, 2017 | 89 | 2017 |
| Evidence for a postnatal doubling of neuron number in the developing human cerebral cortex between 15 months and 6 years WR Shankle, BH Landing, MS Rafii, A Schiano, JM Chen, J Hara Journal of Theoretical Biology 191 (2), 115-140, 1998 | 87 | 1998 |
| The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome MS Rafii, H Wishnek, JB Brewer, MC Donohue, S Ness, WC Mobley, ... Frontiers in behavioral neuroscience 9, 239, 2015 | 85 | 2015 |
Michael C Donohue, PhDAssociate Director of Biostatistics, Alzheimer's Therapeutic Research Institute, USCVerified email at usc.edu